Table 2. Maintenance immunosuppression.

Citation	Immunosuppressant	N	Methods	Outcomes
Griffith et al. 1994 (41)	FK506 vs. CsA	74	Prospective, randomized	AR: 1.2 vs. 2 episodes per 100 patient days, P<0.05 Survival, 1-yr: no difference Bacterial infection: 0.6 vs. 1.5 episodes per 100 patient days, P= NS
Treede et al. 2001 (42)	Tac vs. CsA	50	Prospective, randomized	Freedom from AR, 1 yr: 50% vs. 33.3%, P= NS Treated episodes of AR/100 patient days: 0.225 vs. 0.426, P<0.05 Survival, 1 yr: 73.1% vs. 79.2%, P= NS No difference in infection
Zuckerman et al. 2003 (43)	Tac vs. CsA	74	Prospective, randomized	Freedom from AR, 1-yr: 46% vs. 35%, P=0.774 Treated episodes of AR/100 patient days: 0.22 vs. 0.32, P=0.097 Survival, 1-yr: 71% vs. 82%, P=0.748 Infections: 0.55 vs. 0.7, P=0.059
Hachem et al. 2007 (44)	Tac vs. CsA	90	Prospective RCT	Composite (Cumulative ≥ A3 AR, ≥ B4 LB, BOS 0-p): 50% vs. 84.8%, P=0.002 AR or LB: 41% vs. 63%, P=0.036 Freedom from BOS 0-p: Tac > CsA, P=0.1
Neurohr et al. 2009 (45)	Tac + MMF	155	Retrospective	Freedom from AR, 1-yr: 74.6% Freedom from AR, 5-yr: 59.5% Freedom from BOS, 1-yr: 95.6% Freedom from BOS, 5-yr: 69.5% Survival, 1-yr: 86.4% Survival, 5- yr: 60.3%
Treede et al. 2012 (46)	Tac vs.CsA	249	Prospective, randomized	AR, 3-yr: 67.4% vs. 74.9%, P=0.118 BOS ≥ stage 1-, 3-yr: 11.6% vs. 21.3%, P=0.037 Survival, 1-yr: 84.6% vs. 88.6% (NS) Survival, 3-yr: 78.7% vs. 82.8% (NS) No difference in infection

FK506, tacrolimus; CsA, cyclosporine;AR, acute rejection; NS, not statistically significant; Tac, tacrolimus; RCT, randomized controlled trial; LB, lymphocytic bronchiolitis; BOS, bronchiolitis obliterans syndrome; MMF, mycophenolate mofetil; yr: year.